TrialClinical pharmacology in drug development2021

Single-Dose Pharmacokinetics and Tolerability of the Oral Epidermal Growth Factor Receptor Inhibitor Mobocertinib (TAK-788) in Healthy Volunteers: Low-Fat Meal Effect and Relative Bioavailability of 2 Capsule Products.

Steven Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.